Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tislelizumab in Combination With Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL: a Multicenter, Single-arm, Prospective Clinical Study

NCT07168317 is registered in ClinicalTrials.gov with The Affiliated Hospital of Xuzhou Medical University as lead sponsor.

NCT NCT07168317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07168317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tislelizumab in Combination With Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL: a Multicenter, Single-arm, Prospective Clinical Study
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
August 1, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

new diagnosed angioimmunoblastic t-cell lymphoma